Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 8,500 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $7.49, for a total value of $63,665.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $45,120.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total value of $185,465.00.

Clearside Biomedical, Inc. (CLSD) traded up 0.80% during midday trading on Friday, reaching $7.60. The company’s stock had a trading volume of 224,557 shares. The company’s 50-day moving average price is $7.70 and its 200-day moving average price is $8.08. The company’s market capitalization is $192.55 million. Clearside Biomedical, Inc. has a 1-year low of $6.50 and a 1-year high of $25.08.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The business had revenue of $0.13 million for the quarter. On average, analysts predict that Clearside Biomedical, Inc. will post ($2.10) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 8,500 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/insider-selling-clearside-biomedical-inc-clsd-director-sells-8500-shares-of-stock.html.

Hedge funds have recently made changes to their positions in the business. Marshall Wace North America L.P. acquired a new position in Clearside Biomedical during the 1st quarter worth $1,720,000. Highbridge Capital Management LLC acquired a new position in Clearside Biomedical during the 1st quarter worth $217,000. AWM Investment Company Inc. boosted its position in Clearside Biomedical by 173.0% during the 1st quarter. AWM Investment Company Inc. now owns 341,217 shares of the company’s stock worth $2,709,000 after acquiring an additional 216,217 shares during the period. Granite Investment Partners LLC boosted its position in Clearside Biomedical by 74.8% during the 2nd quarter. Granite Investment Partners LLC now owns 92,941 shares of the company’s stock worth $847,000 after acquiring an additional 39,765 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in Clearside Biomedical during the 1st quarter worth $178,000. Institutional investors own 52.45% of the company’s stock.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised Clearside Biomedical from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Tuesday, July 11th. ValuEngine downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. JMP Securities assumed coverage on Clearside Biomedical in a report on Thursday, May 25th. They set an “outperform” rating and a $21.00 price target for the company. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Clearside Biomedical in a report on Thursday, June 8th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $19.00.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.